Skip to Content
Merck
CN

Key Documents

View All Documentation

SML3836

Delamanid

≥98% (HPLC), mycolic acid biosynthesis inhibitor, powder

Synonym(s):

(2R)-2,3-Dihydro-2-methyl-6-nitro-2-{4-[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]phenoxy]methyl]-imidazo[2,1-b]oxazole, (R)-2-Methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole, Deltyba, OPC 67683, OPC-67683, OPC67683

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C25H25F3N4O6
CAS Number:
681492-22-8
Molecular Weight:
534.48
UNSPSC Code:
51111800
NACRES:
NA.21
MDL number:
MFCD18251539
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Delamanid, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -8 to -12°, c = 0.5 in chloroform-d

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

SMILES string

FC(F)(F)Oc1ccc(cc1)OC2CCN(CC2)c3ccc(cc3)OC[C@@]4(Oc5[n](cc(n5)[N+](=O)[O-])C4)C

InChI

1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1

InChI key

XDAOLTSRNUSPPH-XMMPIXPASA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Delamanid (OPC-67683) is an orally active mycolic acid biosynthesis inhibitor that is effective against both drug-susceptible and drug-resistant strains of M. tuberculosis H37Rv in vitro (MIC = 6 ng/mL) and exhibits significant in vivo efficacy with ~15-fold higher potency than rifampicin (RFP) in mice infected with M. tuberculosis Kurono (fold of lung CFU reduction post 28 days = 41.5 with 5 mg RFP/kg or 0.313 mg delamanid/kg daily orally dosage, 11,000-fold reduction with 0.625 mg delamanid/kg daily orally dosage).
Orally active mycolic acid biosynthesis inhibitor that is effective against drug-resistant strains of M. tuberculosis and is superior to rifampicin in vivo.

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H361d

Hazard Classifications

Repr. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000524409
0000524409
0000501756
0000501756
0000434603

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Delamanid Kills Dormant Mycobacteria In Vitro and in a Guinea Pig Model of Tuberculosis
Antimicrobial Agents and Chemotherapy, 61(6), e02402-e02416 (2017)
Hirofumi Sasaki et al.
Journal of medicinal chemistry, 49(26), 7854-7860 (2006-12-22)
In an effort to develop potent new antituberculosis agents that would be effective against both drug-susceptible and drug-resistant strains of Mycobacterium tuberculosis, we prepared a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles substituted at the 2-position with various phenoxymethyl groups and
Makoto Matsumoto et al.
PLoS medicine, 3(11), e466-e466 (2006-11-30)
Tuberculosis (TB) is still a leading cause of death worldwide. Almost a third of the world's population is infected with TB bacilli, and each year approximately 8 million people develop active TB and 2 million die as a result. Today's

Global Trade Item Number

SKUGTIN
SML3836-10MG04065270362292
SML3836-50MG04065270362308

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service